Skip to main content
OpenTrials
Completed

NCT Number: NCT01723072

Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy

This study will assess the impact of omalizumab on the quality of life improvement when added to the standard therapy in refractory patients suffering from chronic spontaneous urticaria and angioedema.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Spontaneous Urticaria Angioedema Cardiovascular Diseases Chronic Disease Chronic Urticaria Disease Attributes Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Skin Diseases Skin Diseases, Vascular Skin and Connective Tissue Diseases Urticaria Vascular Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Novartis Investigative Site, Mannheim, Baden-Wurttemberg, Germany

Loading trial locations.

About this study

This study will be conducted using a double-blind, placebo-controlled, randomized, multicenter design to investigate the impact of omalizumab on Quality of Life (QoL) in Chronic Spontaneous Urticaria (CSU) and will assess its effectiveness in reducing and/or inhibiting the occurrence, time-course and severity of angioedema episodes.

Omalizumab is administered subcutaneously every 4 weeks as an add-on therapy to the current approved treatment of adult CSU patients. The treatment period is 28 weeks which is followed by an 8-week follow-up. The study aims to enroll approximately 70 patients.

The study is divided into a 2-week screening period, a 28-week double-blind treatment phase with omalizumab or placebo-omalizumab, and an 8-week follow-up phase.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of chronic spontaneous urticaria (CSU) refractory to H1-antihistamine treatment
  • Presence of itch an hives for more than 6 weeks
  • UAS7 score of more than 14 (range 0-42)
  • Patient has history of insufficient response to 4x of the approved dose of H1-antihistamines
  • CSU diagnosis for more than 6 months
  • Angioedema at least 4x in the last 6 months

Exclusion criteria

  • Patients with non urticaria associated angioedema
  • History of hypersensitivity to omalizumab or the rescue medication or to drugs of similar chemical structure
  • Evidence of parasitic infection
  • Previous treatment with omalizumab within the last 6 months prior to screening
  • History of anaphylactic shock
  • Woman who are pregnant or breast feeding
  • Other protocol-defined inclusion/exclusion criteria may apply.

Treatment and study plan

Omalizumab

Biological

Humanized monoclonal antibody against human IgE

Other names: IGE025

Placebo

Drug

Placebo to omalizumab

Other names: Placebo for Omalizumab

Primary outcomes

  1. Mean Change From Baseline Using Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Total Scores During the Study: Unadjusted Analysis and ANCOVA (LOCF) (FAS)

    Time frame: Baseline, 4, 12, 20, 28 and 36 weeks

    The CU-Q2oL is a questionnaire that measures the relative burden of chronic urticaria on subjective well-being. It consists of 23 questions in 3 domains (symptoms, general impairment, difficulties and problems due to urticaria). Participants are asked to respond how much they are troubled by each problem on a 5-point Likert scale (1= not at all to 5= very much). An overall score is calculated and normalized to a scale of 1 to 100.

Secondary outcomes

  1. Number of Angioedema Burdened Days by Study Phase (Observed Cases With Imputation)

    Time frame: Baseline, week 28; and the follow-up period (weeks 29-36)

  2. Mean Time Interval Between Successive Angioedema Episodes of the First 15 Episodes

    Time frame: Baseline to week 28

  3. Change of Angioedema Activity Score (AAS) Total Week Sum Scores: Unadjusted Analysis and ANCOVA (Observed Cases With Imputation)

    Time frame: Baseline to week 28; and follow-up period (to week 36)

    A cumulative activity score, evaluated in the screening period and throughout the study. The records each evening on a daily basis symptoms of itch and hives into a patient diary. min. score = 0 ; max. score= 100

  4. Diameter: Acute Swelling Episodes Within the Screening Period (Week -2 to -1)

    Time frame: week -2 to -1

    data points per group

  5. Diameter: Acute Swelling Episodes at End of Treatment (Weeks 25 to 28)

    Time frame: weeks 25 to 28

    data points per group

  6. Diameter: Acute Swelling Episodes at End of Follow-up(Weeks 33 to 36)

    Time frame: weeks 33 to 36

    data points per group

  7. Shortness of Breath: Acute Swelling Episodes Within the Screening Period (Weeks -2 to -1)

    Time frame: weeks -2 to -1

    data points per group

  8. Shortness of Breath: Acute Swelling Episodes at End of Treatment Period (Weeks 25 to 28)

    Time frame: weeks 25 to 28

    data points per group

  9. Shortness of Breath: Acute Swelling Episodes at End of Follow-up Period (Weeks 33 to 36)

    Time frame: weeks 33 to 36

    data points per group

  10. Change of AE-Q2oL Scores From Baseline to Week 28: Unadjusted Analysis and ANCOVA (Observed Cases)

    Time frame: baseline to week 28; and then follow-up to week 36

    The AE-Q2oL is a questionnaire for patients suffering from angioedema. It consists of 29 questions relevant to angioedema and its specific impact on quality of life. Patients are asked to respond how much they are troubled be each problem on a 5-point Likert scale (1= does not apply to 5= very much). An overall score is calculated and a higher score indicates lower quality of life. A negative change score (week 28 score minus baseline score) indicates improvement.

    Each AE-QoL question has 5 answer options (scored 1-5), with lower and higher scores indicting less and more adverse impact, respectively. The total score is calculated, which is then transformed into a linear scale that ranges from 0 to 100, with a score of 100 indicating the worst possible impairment of HRQoL

  11. Rescue Medication During the Treatment Period

    Time frame: baseline to 28 weeks

  12. Days of Rescue Medication During the Treatment Period

    Time frame: baseline to 28 weeks

    data points per group

  13. Days of Rescue Medication During the Follow-up Period

    Time frame: weeks 33 to 36

    data points per group

  14. Change of UAS7 Total Scores From Baseline to Week 28: Unadjusted Analysis and ANCOVA (Observed Cases)

    Time frame: baseline to week 28; and then follow-up to week 36

    The UAS7 is the sum of urticaria activity scores over a seven day period. The possible range of the weekly UAS7 score is 0-42. 0 means complete response and a better outcome and 42 means no response and a worse outcome.

    Complete UAS7 response is defined as UAS7=0. The UAS7 is the sum of the Hive Severity Score over seven days (HSS7) and the Itch Severity Score over seven days (ISS7) . The Hive Severity Score has a scale of 0 (none) to 3 (intense/severe). Complete hives response is defined as HSS7=0. The Itch Severity Score has a scale of 0 (None) to 3 (Severe (difficult to tolerate)). Complete itch response is defined as ISS7=0

  15. Change of DLQI Scores From Baseline to Week 28: Unadjusted Analysis and ANCOVA (Observed Cases)

    Time frame: baseline to week 28; and follow-up to week 36

    change in Dermatology Quality of Life Index scores

    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy.

Acronym: X-ACT

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Nov 7, 2012
Registry last updated
Sep 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.